Focused On-demand Library for Bardet-Biedl syndrome 7 protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8IWZ6

UPID:

BBS7_HUMAN

Alternative names:

BBS2-like protein 1

Alternative UPACC:

Q8IWZ6; Q4W5P8; Q8N581; Q9NVI4

Background:

The Bardet-Biedl syndrome 7 protein, also known as BBS2-like protein 1, plays a pivotal role in the BBSome complex, crucial for sorting specific membrane proteins to the primary cilia. It is instrumental in ciliogenesis and the sonic hedgehog (SHH) pathway regulation through its interaction with the Rab8 GDP/GTP exchange factor and the LTZL1, facilitating proper ciliary membrane extension and SMO ciliary trafficking.

Therapeutic significance:

Bardet-Biedl syndrome 7, characterized by severe pigmentary retinopathy, obesity, and other systemic manifestations, is directly linked to variants affecting this protein. Understanding the role of Bardet-Biedl syndrome 7 protein could open doors to potential therapeutic strategies, offering hope for targeted interventions in this autosomal recessive disorder.